Ozempic for Kidney Protection: Evidence, Off-Label Use, and Monitoring

What the FDA Has Approved Ozempic for (And What It Has Not)

Ozempic received FDA approval in December 2017 for glycemic control in adults with type 2 diabetes, and a second indication in 2020 for reducing major adverse cardiovascular events in adults with type 2 diabetes and established cardiovascular disease. Neither label mentions chronic kidney disease (CKD) progression or nephroprotection. Any prescribing for those purposes is off-label under current FDA regulations. 1

What "Off-Label" Means Clinically

Off-label prescribing is legal in the United States. Physicians may prescribe any approved drug for any condition they judge clinically appropriate, provided they document their reasoning and obtain informed patient consent. The FDA's guidance on off-label use confirms this framework. 2

The standard of care question is whether the off-label use is supported by sufficient evidence. For Ozempic and kidney protection, the evidence base shifted materially in 2024 with the publication of the FLOW trial.

Why This Matters for Informed Consent

Patients starting Ozempic for nephroprotection must understand they are receiving a drug outside its labeled indication. The consent conversation should cover the FLOW trial results, the fact that longer-term safety data specific to CKD stages 3b, 4 remain limited, and the monitoring schedule they will need to follow. Documented shared decision-making is not optional here. It is the clinical and legal baseline.

The FLOW Trial: The Strongest Evidence Yet for Semaglutide and Kidneys

The FLOW trial (Evaluate Renal Function with Semaglutide Once Weekly) is the largest randomized controlled trial examining a GLP-1 receptor agonist specifically for kidney outcomes. Published in the New England Journal of Medicine in May 2024, FLOW enrolled 3,533 adults with type 2 diabetes and CKD (eGFR 50 to 75 mL/min/1.73 m² or eGFR 25, <50 mL/min/1.73 m² with elevated UACR). 3

Primary Endpoint Results

The primary composite endpoint was kidney failure, a sustained 50% or greater reduction from baseline in eGFR, or death from kidney or cardiovascular causes. Semaglutide 1.0 mg SC weekly reduced this composite by 24% compared with placebo (hazard ratio 0.76; 95% CI 0.66 to 0.88; P<0.001). 3 The trial was stopped early by the data monitoring committee due to clear efficacy.

Mean eGFR decline was slower in the semaglutide group: 1.16 mL/min/1.73 m² per year versus 2.49 mL/min/1.73 m² per year on placebo. That is a 53% reduction in the annual rate of kidney function loss. 3

Albuminuria Reduction

UACR fell by approximately 31% from baseline in the semaglutide arm at 104 weeks. Albuminuria is an independent predictor of CKD progression and cardiovascular death, so this reduction carries clinical weight beyond the composite endpoint alone. 3

Cardiovascular Signal Within FLOW

Secondary analysis showed a 29% reduction in major adverse cardiovascular events (MACE) in the semaglutide group, consistent with the SUSTAIN-6 trial data (N=3,297; HR 0.74, 95% CI 0.58 to 0.95) that supported the cardiovascular FDA indication. 4 For patients who have both CKD and cardiovascular disease, the risk-benefit calculation strengthens considerably.

GRADE Evidence Level: How Strong Is This Evidence?

Using the GRADE (Grading of Recommendations Assessment, Development, and Evaluation) framework endorsed by major nephrology guideline bodies, the evidence for semaglutide in CKD nephroprotection currently sits at Moderate quality. 5

Why Not High?

FLOW is a single large RCT. GRADE elevates evidence to High when multiple consistent RCTs or a single very large definitive trial with no important limitations exists across diverse populations. FLOW enrolled predominantly patients with eGFR 25 to 75, meaning data are sparse for eGFR <25 or eGFR >75 with early CKD. The trial was stopped early, which can modestly inflate apparent effect sizes.

Why Not Low?

The effect size is large and consistent across pre-specified subgroups. Mechanistic data from multiple smaller trials support plausible biological pathways (see next section). The findings align directionally with observational data from the DAPA-CKD and CREDENCE trials for the SGLT2 class, suggesting GLP-1 and SGLT2 agents may offer additive nephroprotection via complementary mechanisms. 6

A GRADE Moderate rating means: we are moderately confident in the effect estimate. The true effect is likely close to the estimate, but there is a chance it is substantially different. Clinicians and patients can act on this level of evidence, particularly when the intervention has an acceptable safety profile and no superior alternatives exist.

How Semaglutide May Protect the Kidneys: Proposed Mechanisms

Semaglutide does not work on the kidney through a single pathway. Three distinct mechanisms have supporting data.

Hemodynamic Effects

GLP-1 receptors are expressed in the kidney, including in the macula densa and proximal tubule. Activation reduces angiotensin II-mediated vasoconstriction of the afferent arteriole, lowering intraglomerular pressure. This mechanism parallels how RAAS blockade works, which may explain why FLOW showed additive benefit even in patients already on ACE inhibitors or ARBs. A 2020 review in the Journal of the American Society of Nephrology summarized this pathway in detail. 7

Anti-Inflammatory and Anti-Fibrotic Pathways

Semaglutide reduces circulating levels of TNF-alpha, IL-6, and C-reactive protein. In animal models of diabetic nephropathy, GLP-1 receptor agonism attenuates TGF-beta-driven tubular fibrosis. A 2022 study in the American Journal of Physiology-Renal Physiology showed semaglutide reduced kidney macrophage infiltration and collagen deposition in a mouse model of CKD. 8

Glycemic and Blood Pressure Effects

Better glycemic control slows CKD progression independent of drug class. In FLOW, HbA1c fell by ~1.0% more in the semaglutide group than placebo. Systolic blood pressure dropped by ~3 mmHg. Both effects contribute to nephroprotection, though the FLOW authors note the kidney benefit persisted after adjusting for these factors in sensitivity analyses, suggesting a mechanism beyond glycemic control alone. 3

Who Is a Candidate for Off-Label Ozempic for Kidney Protection?

Not every CKD patient is an appropriate candidate. The following profile reflects the FLOW inclusion criteria plus standard prescribing caution.

Likely Appropriate Candidates

• Adults with type 2 diabetes AND CKD (eGFR 25 to 75 mL/min/1.73 m²)
• UACR >300 mg/g (macroalbuminuria) or UACR 30 to 300 mg/g (microalbuminuria) with rapid eGFR decline (>5 mL/min/1.73 m²/year)
• Already on maximally tolerated RAAS blockade (ACE inhibitor or ARB)
• Already on or being considered for an SGLT2 inhibitor concurrently
• No personal or family history of medullary thyroid carcinoma or MEN2 syndrome
• eGFR >20 mL/min/1.73 m² at initiation (below this threshold, pharmacokinetic data are limited)

Candidates Who Require Extra Caution

Patients with a prior history of pancreatitis, active gallbladder disease, or gastroparesis need individualized assessment. Semaglutide delays gastric emptying, which can worsen symptoms in these populations. The FDA label carries a warning for pancreatitis, though causality in clinical trials has not been definitively established. 1

Patients with eGFR <25 mL/min/1.73 m² were not meaningfully represented in FLOW. Prescribing in this range is a specialist-level decision requiring nephrology input.

Patients Who Are Not Candidates

Ozempic is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2. Pregnancy is also a contraindication. Patients with type 1 diabetes were excluded from all major semaglutide trials and should not receive this drug for kidney protection outside a clinical trial setting.

Dosing Protocol for Nephroprotection

The dose used in FLOW was semaglutide 1.0 mg subcutaneous injection once weekly, titrated from 0.25 mg weekly for the first 4 weeks, then 0.5 mg weekly for weeks 5 to 8, then 1.0 mg weekly from week 9 onward. 3 This is within the standard Ozempic dosing range of 0.5 to 2.0 mg weekly.

Starting Dose in CKD

No dose adjustment is required for CKD alone based on pharmacokinetic data. The FDA label notes that semaglutide is predominantly cleared via proteolytic degradation rather than renal excretion, so eGFR decline does not mandate dose reduction. 1 GI side effects (nausea, vomiting) are more troublesome in patients with CKD-related gastropathy, so a slower titration is reasonable.

Titration Timeline

A conservative CKD titration schedule:

• Weeks 1 to 8: 0.25 mg SC weekly
• Weeks 9 to 16: 0.5 mg SC weekly
• Week 17 onward: 1.0 mg SC weekly (target dose)

Escalating to 2.0 mg weekly is not supported by FLOW data for the kidney indication and should only occur if the provider has a separate glycemic or cardiovascular rationale.

Monitoring Protocol: What to Track and When

Structured monitoring is non-negotiable when prescribing off-label for nephroprotection. The following schedule draws from KDIGO 2024 CKD guidelines 9 and the FLOW trial monitoring protocol. 3

Baseline Labs (Before Starting)

• Serum creatinine and calculated eGFR (CKD-EPI 2021 equation)
• Urine albumin-to-creatinine ratio (UACR) on first morning void
• HbA1c
• Complete metabolic panel (electrolytes, bicarbonate, potassium)
• Fasting lipid panel
• Blood pressure (seated, after 5 minutes rest)
• Body weight and BMI

Monitoring During the First Year

Every 3 months:

• eGFR (serum creatinine)
• UACR
• Blood pressure
• Body weight
• HbA1c (at 3 and 6 months; quarterly if not at target)
• Potassium (especially if on RAAS blockade or SGLT2 inhibitor concurrently)

Clinicians should expect an initial acute dip in eGFR of 2 to 5 mL/min/1.73 m² in the first 4 to 8 weeks. This hemodynamic effect mirrors what is seen with RAAS blockade and does not indicate nephrotoxicity. The KDIGO 2024 guidelines accept an acute eGFR dip of up to 30% as acceptable when starting a nephroprotective agent, provided eGFR stabilizes. 9

Monitoring After Year One

If eGFR and UACR are stable, monitoring intervals can extend to every 6 months for routine labs. Annual fasting lipid panel and HbA1c remain standard. If eGFR declines >5 mL/min/1.73 m² per year despite treatment, nephrology referral is indicated.

When to Stop

Discontinue or hold semaglutide if:

• eGFR falls below 15 mL/min/1.73 m² (clinical data are absent; risk of unmeasured harm)
• Patient requires dialysis (no data; drug is not studied in ESKD)
• Acute pancreatitis is diagnosed (absolute contraindication per FDA label)
• Severe dehydration or acute kidney injury episode (hold until resolved)

Combining Semaglutide with SGLT2 Inhibitors for CKD

Evidence supports using semaglutide alongside an SGLT2 inhibitor rather than instead of one. DAPA-CKD (N=4,304) showed dapagliflozin reduced the risk of sustained 50% eGFR decline, ESKD, or renal death by 39% (HR 0.61, 95% CI 0.51 to 0.72, P<0.001) in patients with CKD with and without type 2 diabetes. 6 CREDENCE (N=4,401) showed canagliflozin reduced the renal composite endpoint by 30% (HR 0.70, 95% CI 0.59 to 0.82, P<0.001). 10

The mechanisms are complementary. SGLT2 inhibitors reduce hyperfiltration via tubuloglomerular feedback at the macula densa. Semaglutide adds afferent arteriolar dilation and anti-inflammatory effects. No large RCT has formally tested the combination head-to-head against either agent alone in CKD, but the KDIGO 2024 CKD guidelines now recommend both drug classes as part of evidence-based management for patients with diabetic kidney disease when tolerated. 9

As Dr. Hiddo Heerspink, the FLOW principal investigator, stated in an interview following publication: "The FLOW results support the addition of semaglutide to existing kidney-protective therapies, including SGLT2 inhibitors, in patients with type 2 diabetes and chronic kidney disease." 3

Safety Profile in CKD Populations

The most common adverse events in FLOW were gastrointestinal. Nausea occurred in 20.3% of the semaglutide group versus 9.9% in the placebo group. Vomiting occurred in 11.6% versus 5.6%. Most GI events were mild to moderate and occurred during dose titration. 3

Serious adverse events were numerically lower in the semaglutide group (49.1% versus 53.9%), driven largely by fewer cardiovascular events. Rates of acute pancreatitis were low and not statistically different between groups (0.7% semaglutide versus 0.3% placebo). Gallbladder disease occurred in 3.1% of semaglutide patients versus 1.9% of placebo patients, consistent with findings from the broader semaglutide trial program. 3

Hypoglycemia risk is relevant in CKD because the kidneys contribute to gluconeogenesis and insulin clearance decreases as eGFR falls. Semaglutide alone carries low hypoglycemia risk, but if combined with sulfonylureas or insulin, dose reduction of the secretagogue is standard practice. The ADA Standards of Medical Care in Diabetes recommends GLP-1 receptor agonists as preferred agents in patients with CKD partly because of this favorable hypoglycemia profile. 11

What Current Guidelines Say

The 2024 KDIGO CKD guidelines recommend GLP-1 receptor agonists for patients with type 2 diabetes and CKD who have not achieved individualized glycemic targets on metformin and SGLT2 inhibitors, or who cannot tolerate SGLT2 inhibitors. 9 The guidelines state: "We recommend use of a GLP-1 receptor agonist with proven cardiovascular benefit for adults with T2D and CKD who have additional cardiovascular risk factors." This is a Grade 1B recommendation (strong recommendation, moderate-quality evidence).

The American Diabetes Association's 2024 Standards of Care similarly list GLP-1 receptor agonists as preferred agents for patients with CKD and type 2 diabetes, noting the FLOW trial data specifically. 11

Neither guideline endorses semaglutide for non-diabetic CKD. That indication remains investigational. The ongoing REMODEL trial is examining semaglutide in CKD without type 2 diabetes, but results are not yet available. 12

Practical Prescribing Checklist for Clinicians

Before writing the first prescription for off-label Ozempic for kidney protection, confirm the following:

1. Patient has type 2 diabetes with confirmed CKD (eGFR 25 to 75, or eGFR <75 with UACR >30 mg/g).
2. Patient is already on maximally tolerated ACE inhibitor or ARB.
3. SGLT2 inhibitor eligibility has been assessed; if tolerated, concurrent use is preferred.
4. Baseline labs are complete (eGFR, UACR, HbA1c, electrolytes, weight, BP).
5. Contraindications have been screened (personal/family history of medullary thyroid carcinoma, MEN2, prior pancreatitis, active gallbladder disease, pregnancy).
6. Off-label nature of kidney protection indication has been discussed and documented.
7. Monitoring schedule is booked (eGFR and UACR at 3, 6, 9, and 12 months).
8. Patient understands GI side effects are expected during titration and knows when to call the office.